Signum Dermalogix Out-Licenses SIG990 to Dermata Therapeutics for Topical Treatment of Rosacea

PRINCETON, N.J., March 25, 2015 /PRNewswire/ -- Signum Dermalogix, Inc., ("Dermalogix"), a biotechnology company focused on the discovery and development of innovative compounds and products in the field of dermatology, has entered into an agreement with Dermata Therapeutics ("Dermata") to develop a topical product for the treatment of patients with rosacea. SIG990 is a novel, first-in-class anti-inflammatory compound which has the potential to both reduce erythema and decrease the papules and pustules associated with the disease. The Investigational New Drug (IND) application for SIG990 has been cleared by the U.S. Food and Drug Administration (FDA) and SIG990 is thus ready to be evaluated in subjects. Dermata has obtained an exclusive worldwide license to SIG990 and is responsible for the clinical development of the product. Dermalogix will receive milestone payments and royalties on revenues of the product.

Rosacea is a disease that affects between 16-20 million people in the U.S. and typically appears during ages 30 to 40, primarily in women. Symptoms of the disease are significant redness (erythema) of the face, flushing, papules, pustules and telangiectasias (dilated blood vessels). Several drugs to treat rosacea are currently on the market or in development. However, these drugs treat either erythema or inflammatory lesions associated with rosacea, but not both. A safe, topical treatment that addresses both symptoms would be a significant therapeutic option for rosacea patients.

Maxwell Stock, CEO of Signum Dermalogix, Inc., commented, "We are excited to partner with Dermata and look forward to working with their experienced team to advance SIG990 in the clinic.  Partnering allows us to share expertise and thereby provides an effective way of progressing cutting edge research and development. I'd also like to thank the National Institute of Allergy and Infectious Diseases (NIAID) for their support in helping fund this drug development program."

According to David Hale, acting CEO of Dermata, "We believe that this first-in-class compound SIG990 has the potential to be a significant treatment option for patients with rosacea. This disease, while not life-threatening, can have a serious impact on the quality of life of patients. We are excited about moving SIG990 into patients in a Phase 2 clinical trial."

About Signum Dermalogix
Dermalogix was founded in 2011 and is a spinout of Signum Biosciences. Dermalogix is a dermatology focused company developing novel cosmetic functional ingredients and drug compounds. For more information please visit: www.signumdermalogix.com

About Dermata Therapeutics
Dermata Therapeutics, LLC is a private specialty pharmaceutical company based in San Diego, California, involved in licensing and developing innovative prescription drugs for dermatological conditions. For more information about Dermata Therapeutics, please contact David F. Hale at 858-756-2480.

SOURCE Signum Dermalogix, Inc.

Related Links

http://www.signumdermalogix.com